Background: Ejection fraction is a poor parameter to assess left ventricular function in ventricular hypertrophy. It is highlyimportant to analyze aspects of ventricular mechanics that could differentiate cardiac amyloidosis from hypertrophic cardiomyopathy.Objective: The aim of this study was to compare longitudinal strain and other ventricular mechanical parameters betweenpatients with hypertrophic cardiomyopathy and cardiac amyloidosis, both with preserved ejection fraction.Methods: A comparative, prospective study was conducted in 15 patients with cardiac amyloidosis [Group (G) 1] and 15 patientswith hypertrophic cardiomyopathy (G2), both presenting preserved ejection fraction (>50%). Patients were analyzedwith speckle tracking echocardiography and strain and left ventricular (LV) rotational parameters. Longitudinal strain wasobtained from apical 4-, 3- and 2-chamber planes. Circumferential strain and ventricular rotation were obtained from LVtransverse planes. Twist: algebraic sum of apical and basal rotation (°), torsion [twist/LV base-apex distance (o/cm)] and thenew parameters: deformation product (global longitudinal strain × apical circumferential strain); deformation index: [twist/longitudinal strain (°/%)] and ejection fraction/global longitudinal strain ratio were calculated.Results: Patients with cardiac amyloidosis presented significantly lower ejection fraction (58.08%±6.16 vs. 67.15%±8.09;p=0.012) and global longitudinal strain values (–12.61%±4.32 vs. –17.15%±3.95; p=0.008) at the expense of basal segments.No significant differences were found for twist, torsion, and circumferential and radial strain. The product between longitudinalstrain and apical circumferential strain decreased, while the ejection fraction/global longitudinal strain ratio wassignificantly increased in patients with cardiac amyloidosis.Conclusions: The product of longitudinal strain × apical circumferential strain and the ejection fraction/global longitudinalstrain ratio are useful parameters that allow differentiating cardiac amyloidosis from hypertrophic cardiomyopathy patients.